bbgm

16 ms·

121.
by bbgm 11y ago
I used to live in Vietnam for several years. Both my dad and my brother have names starting with "J", which isn't quite around, so in all ID cards their names started with "I".
122.
New AWS public data sets: TCGA and ICGC (large cancer data sets)(aws.amazon.com)
1 points by bbgm 11y ago|0 comments
123.
by bbgm 11y ago
Should they? I can't tell if your comment covers any accent, or just very thick ones. English is my first language (I speak Hindi but am not very comfortable carrying on a conversation in the language). I have lived in the US for alm
124.
by bbgm 11y ago
That's pretty much my understanding as well. It has gone up in the last 15 years but not much.
125.
by bbgm 11y ago
My starting salary at a startup after my PhD was quite a bit higher than $50K in 2000. Even in academia, which pays pitifully, $50K isn't going to cut it anymore.
126.
by bbgm 11y ago
I've been into synths and sound design for a while. But even for someone like me, the last few years have been amazing. Two years ago I had a lot of software and controllers. But now you can get high quality analog keyboard synths a
127.
How to create a custom scheduler for Amazon ECS(aws.amazon.com)
3 points by bbgm 11y ago|0 comments
128.
A biotech education, in progress(blogs.sciencemag.org)
2 points by bbgm 11y ago|0 comments
129.
by bbgm 11y ago
Jazz (which I am more familiar with) is a reasonable analogy. And I agree. You should be able to capture a good studio performance just the way Ornette Coleman and Coltrane could. One thing to note is that jazz has more structure. There
130.
by bbgm 11y ago
In addition to the tonal aspects modern theremins like the Moog Etherwave also make great CV controllers. http://youtu.be/c8uE3Q8p9Jo
131.
by bbgm 11y ago
I suspect that's one of the differences between the CS world and life science world (again broadly speaking). In CS, there tends to be a pretty large gap between academic projects and commercial software projects both in terms of the
132.
by bbgm 11y ago
If you go ask scientists that work in the life sciences, most (at least the ones I know) will say that there are much more fundamental problems that we should be tackling. Synthetic biology is super interesting, and maybe that is the right
133.
Is Andreessen-Horowitz Right That Software's Poised to Eat Healthcare?(forbes.com)
2 points by bbgm 11y ago|0 comments
134.
by bbgm 11y ago
Me too. I am happy to be proven wrong. There are elements of biotech that could use more risk taking, but they seem to ignore some of more "mainstream" (yet relatively knew) technologies where there may be room for innovation.
135.
by bbgm 11y ago
SBIRs have been super effective for many people. It takes time to show technical feasibility and building up real partnerships. SBIRs are well designed for that but also don't allow you to overspend.
136.
by bbgm 11y ago
To date YC has not shown a good understanding of the life sciences. It's not just about a regulatory burden, but the premise of breaking away from academia, of somehow finding a magic bullet and commercializing it, and assuming that b
137.
by bbgm 11y ago
My father will be 70 next year and just went into semi-retirement (where semi-retirement = writing two books). I suspect if there hadn't been a coup in Mali, which resulted in a return to India, he would probably still be working full
138.
by bbgm 11y ago
The current trend [1] would suggest that exascale is not on that kind of trajectory. The dominance of non US countries (especially China) in the Top500 rankings is as much a driver here. 1. http://www.theplatform.net/2015&#
139.
by bbgm 11y ago
My behavior has completely changed in the 2 months I've had one. Notifications are the biggest one. My phone stays in my pocket more often, I use it very actively to pay for things, and of course as a tracker. Is it a must have? No,
140.
by bbgm 11y ago
Biotech startups with a computational method of target discovery that is "different from the norm at Big Pharma" have been around at least since the late 90s. The problem is targets are cheap. Validating those targets is expensi
141.
by bbgm 11y ago
They haven't for a while. Some of the claims, at least in this story, are way over the top.
142.
by bbgm 11y ago
My biggest fear is that the folks at YC actually believe claims like that.
143.
by bbgm 11y ago
The thing is this kind of idea is not new. Finding new targets is hard science that needs a ton of experiments to validate that your theoretical models even work. For now this is low risk and no cost to the pharma partner, but it's a
144.
by bbgm 11y ago
If you've used MyChart you've used EPIC. Both the hospital systems I've used here in the greater Seattle area use Epic for their EHR systems.
145.
by bbgm 11y ago
If you are bootstrapped it is a huge barrier. And Meme is not that bad. There are others that are far worse. I once tried using Modeller purely for hobby projects (science was not even my day job) but was denied. That's a problem.
146.
by bbgm 11y ago
Speaking for the chemical reaction - yes. That is exactly what should be possible. Some reactions are hard to reproduce and labs spend years trying to figure out how to do so. Without that you really don't have good science. The key
147.
The myths of bioinformatics software(liorpachter.wordpress.com)
86 points by bbgm 11y ago|72 comments
148.
by bbgm 11y ago
All my experience working in and with biotech/pharma has taught me that your experiments will usually fail. The later they fail the more expensive. Biology is ridiculously hard and certainly not predictable. Aspects are reproducible
149.
by bbgm 11y ago
I think it's a bit of both. I stopped checking bags in because of all the hassles - delays, lost bags, etc. This was well before airlines started charging for checked bags, and I know many others (mostly frequent travelers) in the sa
150.
by bbgm 11y ago
This is partly in line with my experiences. It's more subtle than it comes across in the article. I've thanked servers, taxi drivers, and others, but don't recall thanking a bus driver. I have thanked my parents and they&#x2

More ›